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Curative surgical treatment of recurrent, locally advanced dermatofibrosarcoma protuberans is often limited owing
to a close relation of the tumor with important anatomical structures. Targeted therapy with imatinib, a tyrosine
kinase inhibitor, may cause significant reduction of tumor volume, thereby enabling radical surgery. This treatment
strategy, therefore, offers a chance of cure for selected patients with advanced dermatofibrosarcoma protuberans.
In addition, preoperative treatment with imatinib may decrease possible disfigurement related to radical surgery for
large tumors.
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Dermatofibrosarcoma protuberans (DFSP), as a low- to
intermediate-grade soft tissue sarcoma, is a locally ag-
gressive tumor owing to its infiltrative growth pattern.
Following initial resection, local recurrence is a common
dilemma, while distant metastases usually are rare (5%)
[1]. DFSP comprises around 2% to 6% of all soft tissue
sarcomas and its incidence is almost double among
black compared to white persons [2,3].
Diagnosis of DFSP is generally made by core needle or
open biopsy. Immunohistochemical analysis (CD34 anti-
gen expression) can be used in addition to histological
tumor evaluation. In addition, magnetic resonance im-
aging is helpful in preoperative planning to evaluate the
local extent of the tumor. Screening for distant metasta-
ses is performed by computed tomography imaging of
the chest.
Radical surgical resection is the first choice of treat-
ment of DFSP. Minimal tumor-free resection margins of
2 to 3 cm are recommended owing to the relatively high
risk of local recurrence (up to 50%) [4-6]. However, such* Correspondence: j.vd.hage@nki.nl
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reproduction in any medium, provided the ormargins generally are difficult to obtain due to the ana-
tomical location of the tumor. Postoperative radiother-
apy is often administered to reduce the risk of local
recurrence [7]. In cases of locally advanced tumor
growth in close relation to vital structures, a multidiscip-
linary approach including reconstructive surgery is often
needed.
For patients with unresectable disease, the application
of targeted therapy with imatinib has recently been eval-
uated. In most DFSP patients (around 90%), a t(17;22)
chromosomal translocation leads to upregulation of the
platelet-derived growth factor B pathway, resulting in
uncontrolled cell division [1]. Imatinib, originally devel-
oped to treat patients with chronic myelogenous
leukemia, acts through inhibition of tyrosine kinase,
thereby blocking the platelet-derived growth factor B
(PDGFB) pathway and causing tumor cell apoptosis
[1,8]. Results of imatinib treatment in patients with
DFSP are encouraging but still limited. Some case series
have recently been published, reporting favorable re-
sponses in patients with recurrent or metastatic disease
[8,9]. Interestingly, the presence of a t(17;22) chromo-
somal translocation seems to be associated with the re-
sponse to imatinib [10].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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A 47-year-old African man was referred to our clinic
with a recurrent, locally advanced DFSP of the right
periclavicular region. Primary resection of a DFSP in the
same region was performed approximately six years earl-
ier, followed by two additional resections for recurrent
disease. Local radiotherapy (60 Gray) was administered
after the last resection.
The current locally advanced tumor recurrence devel-
oped one year before the patient’s visit to our hospital.
At physical examination, local signs of radiotherapy
damage to the skin were noted in the right periclavicular
region. Tumor was palpated underneath the clavicula as
well as on the right side of the lower neck. Additional
magnetic resonance imaging showed the presence of lo-
cally advanced tumor growth with a close relation to the
clavicula and internal jugular vein, limiting the possibil-
ities of radical surgery (Figure 1). No signs of distant
metastases were demonstrated. Ultrasound core needle
biopsy in the referring center suggested a high-grade soft
tissue tumor, possibly fibrosarcoma, potentially due to
malignant dedifferentiation of the original DFSP. Re-
peated biopsy in our clinic showed a low-grade mesen-
chymal tumor, positive for CD34, suggestive of DFSP.
Fluorescence in situ hybridization (FISH) analysis re-
vealed the presence of a t(17;22) chromosomal trans-
location, confirming the diagnosis of DFSP. 
Figure 1 Magnetic resonance imaging showing the presence of
locally advanced tumor growth with a close relation to the
clavicula and internal jugular vein.The patient was subsequently treated with imatinib
400 mg daily according to our institutional protocol for
locally advanced gastrointestinal stromal tumors (GIST),
resulting in a partial tumor response after three months
of treatment (Figure 2). Assessment after six months
showed stable disease and no signs of distant metastases.
Due to the marked tumor response, radical surgery
could now be performed without sacrificing vital struc-
tures. The tumor was resected en bloc with part of the
underlying pectoralis major muscle, the periosteum of
the clavicle and part of the sternocleidomastoid muscle.
The internal jugular vein was free of tumor and, there-
fore, not sacrificed. Resection margins were macroscop-
ically tumor-free. A plastic surgeon was consulted to
close the defect by transposition of the pectoralis major
muscle in combination with a split skin graft. The pa-
tient recovered without any complications.
The pathology report showed a radically resected low-
grade mesenchymal tumor, with a near complete tumor
response. Tumor-free margins were less than 1 mm. Im-
munohistochemical and RT-PCR analysis confirmed the
diagnosis of DFSP. The lesion was positive for vimentin,
aSMA and CD34, and negative for caldesmon, myoD1,
CD117, desmin, NF, Cam5.2, pankeratin, Myf4 and S100
markers. RT-PCR sequencing was performed for C-KIT
and PDGFR-alpha mutations to differentiate between
GIST and DFSP. No mutations in exons 9, 11, 13 and 17 
Figure 2 Magnetic resonance imaging showing partial tumor
response after three months of imatinib treatment.
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found in exons 12, 14 and 18 of the PDGFR-alpha gene.
The patient is currently followed at three month inter-
vals by magnetic resonance imaging of the operated area.
Computed tomography scanning of the chest will be
performed annually. To reduce the risk of local recur-
rence, imatinib treatment will be continued for two years
postoperatively.
Conclusions
Although DFSP is commonly a low-grade tumor, ap-
proximately 15% of cases contain a high-grade sarcoma
component. Also, high-grade dedifferentiation may
occur in the course of the disease [11]. The patient de-
scribed in our case presented with initially unresectable
recurrent DFSP of the periclavicular region, with signs
of high-grade dedifferentiation at core biopsy. Subse-
quently, his clinical response to imatinib was significant,
resulting in the possibility of radical surgery. In addition,
histological assessment of the resected tumor revealed a
near complete tumor response. A positive relation be-
tween high-grade subtypes of DFSP and response to
imatinib may, therefore, be suggested, emphasizing the
efficiency of this targeted therapy in selected patients. A
possible explanation of this relationship may be a higher
incidence of the t(17;22) chromosomal translocation in
patients with high-grade DFSP [11,12].
Taken together, our results strengthen the use of imatinib
in downsizing initially unresectable DFSP, offering a chance
of cure for selected patients following secondary surgery.
In addition, for upfront resectable patients, preoperative
treatment with imatinib may decrease possible disfigure-
ment related to radical surgery for large tumors.
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